Federal regulators just approved the first flu shot ever built with mRNA technology, but people 65 and older are getting it through a faster approval track that usually means the evidence isn’t fully locked down yet.
Story Snapshot
- The FDA approved Moderna’s mFLUSIVA, the first mRNA-based flu vaccine ever cleared for use in the United States.
- Adults 50 to 64 got standard, full approval. Adults 65 and older got a faster “accelerated approval” instead.
- Moderna must now run a follow-up study to prove the shot actually protects people 65 and older.
- The approval follows a stunning reversal — the FDA initially refused to even review the vaccine earlier this year.
- An FDA advisory panel voted 9-0, unanimously, that the shot’s benefits outweigh its risks.
A New Kind of Flu Shot Clears Federal Review
The Food and Drug Administration approved Moderna’s mFLUSIVA on August 5, marking the first time regulators have cleared a seasonal flu vaccine built with messenger RNA technology, the same platform used in Moderna’s COVID-19 shots. The vaccine is cleared for all adults 50 and older ahead of the 2026-2027 flu season.
Two Age Groups, Two Different Approval Standards
Regulators did not treat all adults the same. Adults 50 to 64 received a standard, traditional approval. Adults 65 and older received something called accelerated approval, a pathway the FDA typically reserves for cases where the full proof of effectiveness isn’t finished yet. Moderna must now run an additional study to confirm the vaccine truly works for the older group.
Company data showed the shot cut confirmed flu cases by 27% compared to a standard flu vaccine in the clinical trial covering adults 50 to 64. That trial ran for a single flu season, and outside reviewers have noted there was limited data on older, frailer patients before approval.
Regulators Reversed an Earlier Rejection
The path to approval was rocky. In February, the FDA initially refused to even process Moderna’s application, a decision that stunned Wall Street and the health care industry. Weeks later, the agency reversed course and agreed to review the vaccine after Moderna proposed a revised regulatory approach.
That about-face raised questions inside and outside the agency about how the decision got made. The reversal came before an advisory committee ever weighed in, meaning the shift in position happened at the staff level, not through the panel of outside experts who later reviewed the data.
Unanimous Panel Vote Comes Amid Lingering Doubts
In June, the FDA’s outside vaccine advisory committee voted 9-0 that the shot’s benefits outweigh its risks for both age groups, and the panel said it found no valid new safety concerns during its review. That unanimous vote came just before the earlier public dispute over the FDA’s initial refusal to review the application.
What’s not accurate:
The language about “increased risks of myocarditis and pericarditis… highest in males 12 through 24 years of age” is not in the mFLUSIVA (Moderna mRNA flu vaccine) fact sheet or prescribing information. That exact wording comes from the mRNA COVID-19 vaccine…— Katt (@Katt3jc1) August 7, 2026
Even with unanimous backing, the split approval standard has fueled debate online, especially among people still wary of mRNA vaccines after the COVID-19 pandemic. For older Americans and their families, the key fact to know is simple: the shot for people 65 and up is still being watched closely, with a required follow-up study yet to confirm how well it actually protects that age group in the real world.
The episode reflects a pattern many Americans on both the left and right have grown used to watching: an agency reverses itself, moves quickly once political and market pressure builds, and then asks the public to trust a process that even its own regulators treated differently depending on who the vaccine is for.
Sources:
abcnews.com, npr.org, newswire.com, cidrap.umn.edu, finance.yahoo.com
